INTRODUCTION
Assessment of IFNL3 genotype is a routine clinical practice along other prognostic tests including assessment of baseline viral load, checking patient's age, gender, body mass index (BMI), liver physiopathology and the viral genotype before a patient is worked up to decide for appropriate hepatitis C virus (HCV) treatment course. Involvement of host genetics in predicting treatment outcome was reported concurrently by three seminal letters to Nature in 2009 by Ge et al. (2009) , Tanaka et al. (2009) and Suppiah et al. (2009) in the first genome-wide association study for HCV patients with genotype 1. Interestingly the same genomic regions around IFNL3 were identified by all to have strong association with sustained virological response (SVR). However, Tanaka et al. (2009) ) and Suppiah et al. (2009) indicated single-nucleotide polymorphism (SNP) rs8099917, while Ge et al. (2009) reported rs12979860 as the strongest predictive SNP for treatment response to IFN/ribavirin.
IFNL3 gene forms a cytokine gene cluster along with IL28A and IL29 on chromosome 19 (19q13) . Cytokines encoded by these genes are virally induced type III IFNs (IFN-ls) having strong antiviral activities. These genes provide immunity to viral infection in an alternate capacity to type I IFNs by interacting with a heterodimer class II cytokine receptor (IL10Rb and IL28Ra, encoded by IL28RA) (Kotenko et al., 2003; Sheppard et al., 2003) . IFN-l mediates protection against viral infection by a steady expression of IFN-stimulated genes, the same genes that are rapidly and more transiently induced by IFN-a (Marcello et al., 2006) , signifying that IFN-l may be responsible for a slower, however a more continual antiviral response. This might be a way why a genetic variant may affect the treatment response to IFN/ribavirin. A number of studies have implicated the functional aspect played by IFNL3 polymorphisms and indicate the impact these polymorphisms may have on the treatment outcome (Bibert et McFarland et al., 2014; Prokunina-Olsson et al., 2013; Lu et al., 2015; O'Brien et al., 2015) .
After Ge et al. (2009 ), Tanaka et al. (2009 and Suppiah et al. (2009) most of the research was focused on these SNPs and their association with response to viral infection was either spontaneous clearance or treatment induced (Sharafi & Alavian 2011; Jim enez-Sousa et al., 2013) . They established very strong association of SNPs (rs8099917 and rs12979860), with the SVR in patients with genotype 1 (Ge et al., 2009; Rauch et al., 2010; Suppiah et al., 2009; Tanaka et al., 2009; Lin et al., 2011) . The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) 2011 recommendations for HCV management incorporated IFNL3 genotyping in their guidelines (Anon, 2011; Ghany et al., 2011) . However, the majority of the studies that followed focused mainly on patients with genotype 1.
Later, Asselah et al. (2012) confirmed IFNL3 polymorphism's association with response to treatment in genotype 4 patients. In contrast, investigations on patients with genotypes 2 and 3 yielded contraindicative results. Some reported associations, while others failed to find any such associations between IFNL3 polymorphisms and treatment response (Rauch et al., 2010; Mangia et al., 2010; Moghaddam et al., 2011; Sarrazin et al., 2011) . Furthermore, an association meta-analyses also suggested that although IFNL3 polymorphisms are associated with treatment response in patients with genotypes 1 and 4, IFNL3 genotyping has a restricted predictive value in the case of patients with genotypes 2 and 3 (Jia et al., 2012; Jim enez-Sousa et al., 2013) .
Considering the fact that one-third of all chronic HCV patients are infected with genotype 3 and it is the second most predominant genotype, the importance of ascertaining whether IFNL3 polymorphisms are associated with response to treatment or not in HCV patients with genotype 3 is imperative. Here, for this very reason, we have investigated the predictive value of five IFNL3 SNPs to indicate treatment outcome in patients with genotype 3.
RESULTS
Three hundred and sixty-eight patients (n=368) chronically infected with HCV and completing a course of interferon plus ribavirin treatment regime were investigated to find out the association between five IFNL3 SNPs and SVR in patients with genotype 3. Demographic and basic clinical attributes of the enlisted patients are shown in Table 1 . Patients fulfilling the inclusion criterion had HCV genotype 3 and were positive for serum HCV RNA. From the total, 241 patients (65.5 %) achieved SVR, while the remaining 127 patients (34.5 %) failed to show sustained response. Five IFNL3 SNPs on chromosome 19, within position 39 241 143 and 39 253 181 were studied for their association with SVR (Table 2) .
Association of response with baseline demographic attributes in HCV patients with genotype 3
Association of low initial viral load (HCV RNA <0.46106 IU ml À1 ), early stages of fibrosis (F0-F2 on Metavir fibrosis score), good BMI, younger age and the achievement of rapid virologic response and early virologic response, is well documented with a favourable chance of achieving SVR (Lin et al., 2011; Shirakawa et al., 2008) . We found strong association between alanine transaminase (ALT) and response; however, we did not find any significant association between baseline viral load and age (Table 3 ). Lack of association between age and treatment response was because both groups were from approximately the same age group. A larger and more diverse cohort may have yielded different results. Furthermore, it is an observation in our population that usually baseline viral load fails to predict the treatment outcome and only the viral loads at the extremes, lower or higher, are of any predictive value. Results of the one-way ANOVA analyses of response compared to age, gender and ALTs for current sample data are given in Table 3 .
Neither of the favourable genotypes CC (rs12979860) or TT (rs8099917) showed any association with IFN/ribavirin treatment outcome AA (64.7 %), CC (41 %), CA (59.6 %), TT (63.9 %) and GG (64 %) were indicated as the most common genotypes for rs12980275, rs12979860, rs9109886, rs8099917 and rs7248668, respectively, in the case of responders and nonresponders. We did not find any statistically significant association between the favourable genotypes, for any of the SNPs we genotyped, and the SVR (Table 2) . Furthermore, similar allelic percentages were observed for responders and non-responders for all of the genotyped SNPs (Fig. 1 ).
Viral clearance and persistence of infection was the same for the genotype distribution among our sample data. Multivariate as well as univariate analysis for the SNPs with SVR did not report any statistically significant difference between the responders and non-responders.
IFNL3 SNPs haplotypes were similar for responders and non-responders
We assessed whether the five IFNL3 SNPs are associated with SVR in form of a haplotype. We found that the results for haplotype estimation for responders and nonresponders were identical. This indicated same allelic distribution for responders and non-responders. The top five haplotypes estimated are shown (Fig. 2) and this indicated that none of the IFNL3 SNP we genotyped in our study are associated with SVR, neither individually nor in haplotype. The complete list of the estimated haplotypes is given as supplementary material (PHASE results, Files S1-S4, available in the online Supplementary Material).
DISCUSSION
Genotype 3 is the second most prevalent HCV genotype after genotype 1 and is the most common in South Asia, i.e. Pakistan and India (Messina et al., 2015) . Healthcare costs are a serious issue in these Third World countries and have stern economic implications. Therefore, accurate prognosis and the predictive ability of pre-treatment tests are of critical importance to reduce subsequent economic burden. Genotyping favourable alleles of IFNL3 polymorphisms are considered an important host genetic prognostic marker for successful achievement of SVR in patients with genotype 1 (Lin et al., 2011) . However for genotype 3, contradicting results have been reported. Therefore, we investigated the predictive value of IFNL3 polymorphisms in HCV patients with genotype 3. The aim was to investigate whether IFNL3 polymorphisms can predict treatment outcome and SVR in patients with genotype 3, since some studies reported that IFNL3 polymorphisms have a restricted predictive value in case of genotype 3 (Jia et al., 2012) . Interestingly, not only did we fail to find any association of treatment outcome with rs12979860 but also did not find any association for the rest of the SNPs, including rs8099917 which is regarded as the second most important SVR predictor, especially for Asians (Jia et al., 2012; Jim enez-Sousa et al., 2013) . Normally IFNL3 association studies are combined with other prognostic markers like age, gender and baseline viral load. However, it warrants further investigation as to whether IFNL3 SNPs can independently predict treatment outcome. The lack of association we report between IFNL3 and response clearly indicates that IFNL3 SNPs are poor predictors of treatment outcome in an independent capacity in patients with genotype 3.
The haplotype estimations for responders and non-responders were also almost similar. Asian populations (our data set) have a significantly better response to IFN/ribavirin therapy than Caucasians even in the case of genotype 1 (Ge et al., 2009) . It expounds inherent host genetic and other factors for Asians that may result in better viral clearance. Combining such factors with the genotype 3, these patients are possibly well equipped to clear infection after treatment. Host genetic predisposition, therefore, could be of lesser predictive value in this context being masked by the predictive value of other factors.
Furthermore, the latest recommendations by EASL on the treatment of HCV 2015 has listed that IFNL3 genotyping has lost its relevance with the advent of the new direct-acting agents. However, IFNL3 genotyping may still have predictive value in combined therapy instances (Anon, 2015) . Therefore, we propose that if IFNL3 SNPs are of no predictive value, IFNL3 genotyping can be left out of the initial patient workup by the clinicians for subsequent treatment regime choice. This will certainly reduce the economic burden of overall treatment cost for the patient. It is still crucial to note that other prognostic markers, baseline viral load, age, gender, BMI, liver physiopathology and especially HCV genotype will remain important to predict treatment outcome. Nevertheless, it is imperative that further studies in this regard are conducted to ascertain the presence or absence of association between IFNL3 genotypes and SVR after IFN/ribavirin therapy in patients with genotype 3.
HCV treatment in resource-limited set-ups heavily depends upon the prognostic capacity of the pre-treatment tests. However, the cost of these tests and the treatment must be bearable for the common. IFNL3 is a very important prognostic marker in case of genotype 1, yet we report in this study that it has limited predictive value in patients with genotype 3. Based on our results, we suggest that patients with genotype 3 can be worked up for treatment without determining their IFNL3 genotype. Extensive analyses have been conducted for HCV patients with genotype 1, though not all results can be extended for other genotypes. Genotype 3 is the second most common HCV genotype and may infect more than 30 million individuals (in Pakistan and India alone) (Messina et al., 2015) . Thus, more studies focused on HCV patients with genotype 3 are required. The patients were divided into two groups based on their treatment response, i.e. responders, who achieved SVR and non-responders who failed to achieve SVR. Patients, who cleared infection and their viral load remained below detectable limit (using Qiagen artus® HCV RG RT-PCR kit for quantification) after 6 months from the end of treatment, were considered as responders. For HCV genotyping, viral RNA was extracted using QIAamp Viral RNA Mini kit following the manufacturer's instructions. Then HCV genotype was determined by using RNA UltraSenseÔ One-Step Quantitative RT-PCR system and in-house designed primers (Ohno et al., 1997) .
Ethical statement. Enlisted patients gave signed consent to participate in the study after they were well informed about the investigation. The investigation was approved by the ethical committee and institutional review board of respective institutions.
IFNL3 genotyping. Allele-specific PCR was used for the genotyping of rs12980275, rs7248668 and rs8109886. Primers were designed using online primer designing tool, Primer3 (Rozen & Skaletsky, 2000) . Primer sequences and expected band sizes are mentioned in Table S1 . For each sample two PCR reactions were performed, each containing 100 ng of genomic DNA, control primers and either of the allele-specific primer. PCR products were visualized on 2 % agarose gel and alleles were assigned based on the presence or absence of specific sized band (Table S1 ).
For the genotyping of rs12979860 and rs8099917, specific SNP genotyping assay based on TaqMan ® allelic discrimination was used (Applied Biosystems; Part no. 4331349, 4351379). Real-time PCR reactions were performed on an ABI prism 7000 Sequence Detection system (Applied Biosystems).
Statistical analysis. Chi-square, means and SD as well as univariate and multivariate analyses were performed for the sample data. Logistic analyses, univariate and multivariate, were conducted to predict SVR using patients' age, gender, ALT and the IFNL3 SNPs. Some of the data for rs12979860 has previously been published in the form of a short communication (Hashmi et al., 2014) . One-way ANOVA was calculated for the response and patients' age, gender and ALTs.
Chi-square was computed using online chi-square calculator 'c 2 Calculations' (http://turner.faculty.swau.edu/mathematics/math241/materials/contablecalc/). Except for chi-square calculations, the rest of the statistical analyses was performed with statistical software SPSS for Windows (version 20; SPSS).
Haplotype estimation. The haplotypes for responders and non-responders were estimated using PHASE v2.1 (Stephens & Scheet, 2005; Stephens et al., 2001) . PHASE is software used for the haplotype reconstruction and to determine the rate of recombination estimated from the sample data.
Statistical significance. P values<0.05 were considered significant in two-tailed tests.
